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Abstract 
Overuse and inappropriate use of antibiotics have been associated with increased rates of antimicrobial resistance and increased 
healthcare expenditures.  Tracking inpatient antimicrobial use has helped quantify the value of stewardship programs aimed at 
improving the rational use of antibiotics among hospitalized patients.  Unfortunately, similar methods for tracking and assessing 
antibiotic use in the outpatient setting have not been well described.  We developed a novel method to capture trends and assess 
appropriateness of antibiotic usage.  This strategy is based on identification of antimicrobial prescriptions in an electronic medical 
record system, linking prescribing to patient data, and capturing information regarding dosing and indications for use.  Using 
information on dose, frequency, and duration of the antibiotic prescribed, a parameter to quantify antibiotic exposure (Prescribed 
Therapeutic Regimen, PTR) is calculated.  This parameter is compared to a database of information on agents recommended in 
published guidelines (Recommended Therapeutic Regimen, RTR).  By linking an ICD-9 code and the prescribed antibiotic we 
determine the appropriateness of the PTR by comparing it to the RTR for a given indication.  Data are used to establish a baseline 
pattern of antibiotic use in the clinic to gauge the impact of future stewardship activities.  Additionally, individual clinics and 
prescribers are given a snapshot of their antibiotic use compared to other clinics and prescribers.  This is a novel means of describing 
antibiotic use in the outpatient setting that could serve as a standardized model for various adult and pediatric outpatient practices. 
 
 
 
Introduction  
Outpatient antibiotic use has been correlated with the 
emergence of resistance among microbes and community 
acquisition of infections secondary to resistant bacteria such 
as Streptococcus pneumoniae, Staphylococcus aureus, and 
Escherichia coli.1-3  Importantly, infections caused by resistant 
pathogens have been associated with increased treatment 
costs, poorer outcomes, and increased rates of hospital 
admission and readmission.2  Unfortunately, population data 
continue to suggest that antimicrobial prescribing patterns for 
the management of various community-acquired conditions 
such as upper respiratory tract infections (e.g., pharyngitis and 
sinusitis), urinary tract infections, pneumonia, and cellulitis 
continue to be excessive or inappropriate.3-12   
 
Antibiotics are over-prescribed for conditions that have a low 
probability of being caused by bacterial pathogens, and the  
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choice of agent and duration of therapy often are not 
congruent with published guidelines.4-7, 9  Numerous studies 
suggest that overuse of antibiotics in the outpatient setting is a 
significant problem.3-12  Respiratory tract infections represent 
a constellation of diagnoses for which outpatient antibiotic use 
has been identified as particularly concerning.3-9  Furthermore, 
inappropriate use of antibiotics for urinary tract infections and 
skin and skin structure infections has led to the emergence of 
increasingly resistant pathogens being identified as the source 
of these infections.  A report from the Center for Healthcare 
Research & Transformation at the University of Michigan 
summarized antibiotic prescribing trends in Michigan from 
2007-2009.1  Among adult patients, it was noted that 
approximately 50% of antibiotic prescriptions in a third party 
payer system received antibiotics considered to be “antibiotics 
of concern” (i.e., broad spectrum antibiotics) by the National 
Committee for Quality Assurance (NCQA).   In response to data 
such as these, The National Action Plan for Combating 
Antibiotic-Resistant Bacteria was developed by the Task Force 
for Combating Antibiotic-Resistant Bacteria in response to 
Executive Order 13676.13, 14  
 
Among the outcomes stated by the Task Force, was to reduce 
inappropriate antibiotic use by 50% in the outpatient setting 
by the year 2020.15  
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Although antimicrobial stewardship programs have been 
developed to facilitate the appropriate use of antibiotics 
within hospitals, few similar programs exist to assist with the 
management of antibiotic usage in outpatient settings.  One 
complicating factor has been lack of a standardized means to 
assess and benchmark antibiotic utilization in the ambulatory 
setting.  Inpatient antimicrobial stewardship programs use 
parameters such as the Defined Daily Dose (DDD) or Days of 
Therapy (DOT) to measure antibiotic use.  DDD is defined as 
the assumed average maintenance dose per day for a drug 
used for its main indication.16   Although widely used, it has 
been recognized that the value of DDD is limited because this 
parameter does not take into account dosing variability for 
different infections or individual characteristics such as age, 
weight, or renal/hepatic function.  As a result, the utility of 
DDD in a diverse population over a range of infectious 
processes is questionable. 
 
Unlike the hospital setting where purchasing data and 
dispensing records are readily available and for evaluation of 
antimicrobial usage patterns, analogous data may be difficult 
to obtain in clinic setting.  The primary challenge in the 
outpatient setting is that antimicrobials are prescribed in one 
setting and the prescription is often filled in another. 
Additionally, patients from one clinic go to a myriad of 
different pharmacies.  These factors have made it difficult to 
link prescribing to dispensing in the outpatient setting.  As a 
result, most of the data reported regarding antibiotic use in 
the ambulatory care setting have come from wholesalers or 
insurance claims.  Although these data may provide a global 
idea of antibiotic use, they can be cumbersome, time 
consuming, and costly to collect.  This degree of information is 
virtually useless with respect tracking the impact of 
stewardship interventions at the clinic or prescriber level.  
These data provide limited information regarding the 
appropriateness of the antibiotic, dose, or duration for a given 
indication and patient and can be difficult for individual clinics 
to obtain.  Additionally, these data are not provided in a timely 
fashion, thus further limiting its clinical utility.  For these 
reasons, it impractical to attempt to build and assess an 
outpatient antimicrobial stewardship program using these 
data sources. 
 
Recognizing the limitations associated with existing strategies 
for gathering outpatient antimicrobial usage data at a clinic 
level, the World Health Organization (WHO) piloted the use of 
prescription records as a means to assess antibiotic use.17  
Although the concept of using prescription records for tracking 
outpatient antibiotic use was insightful, it was still 
recommended to compare regimens to DDD.  Unfortunately, 
comparison of individual antimicrobial regimens with DDD is 
associated with the same one-size fits all limitation noted 
earlier. 
 
Recognizing the need for an improved means with which to 
track and assess the appropriateness of antimicrobial use the 
outpatient setting, we developed a novel strategy to 
accomplish this task.  The primary purpose of this manuscript 
is to describe a novel, robust method to track and assess the 
appropriateness of antimicrobial prescribing in an academic 
medical clinic among various patient populations and for 
numerous indications.  Antimicrobial utilization data 
generated by these methods are intended to allow for internal 
and external benchmarking globally, by indication, by specialty 
clinic, and by prescriber and provide a platform upon which to 
gauge the impact of stewardship initiatives in an outpatient 
setting. 
 
Description of Methods 
Methods were developed for use at the Western Michigan 
University Homer Stryker M. D. School of Medicine Clinics 
(WMed) in Kalamazoo, Michigan.  There are 10 individual 
clinics (Family Medicine, Infectious Diseases, Internal 
Medicine, Internal Medicine Subspecialties, Medicine-
Pediatrics, Orthopedics, Pediatrics, Pediatric-Subspecialties, 
Psychiatry, and Surgery) located within the WMed Clinics.  
There are approximately 30,000 active patients seen by the 
various clinics. 
  
Data Collection Procedures  
Data are retrieved from the WMed electronic medical record 
(EMR) (eClinicalWorks version 10) for all patients seen in clinic 
for a given time period.  Demographic data (medical record 
number, age, sex, ethnicity) are collected at the patient level, 
while information regarding antibiotic allergies, diagnosis 
code(s), provider, provider description (e.g. resident, faculty, 
physician assistant, etc.), and a full medication list are 
collected at the patient visit level (Table 1).   
 
Episodes of antimicrobial prescribing are identified by 
assigning a dichotomous variable to the medications 
prescribed at each visit according to an antibiotic or non-
antibiotic scheme.  Additionally, antibiotic count variables are 
created to indicate the number of antibiotics prescribed at 
each visit, and the number of antibiotics prescribed for each 
patient during the targeted timeframe. Antibiotic count 
variables can then be used to estimate a per-patient antibiotic 
prescription rate.  For each antibiotic prescribed, the 
indication for use is identified by examining the posted 
International Statistical Classification of Diseases and Related 
Health Problems (ICD-9) Codes for the clinic visit at which the 
agent was prescribed (Table 2).18  By cross-referencing 
antibiotic prescriptions with ICD-9 codes, the antibiotic usage 
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rate for specific diagnoses can be assessed.  Additionally, 
patient data that may influence selection of an antibiotic or 
dose such as allergic reaction, body mass index, and renal 
function, are collected from encounters as close to the 
antibiotic prescription date as possible.  Antibiotics prescribed 
for the selected indications are compared to the agents 
recommended for use in published treatment guidelines.19-24  
If the prescribed antibiotic is not listed as a recommended 
agent within the guidelines, its use is deemed inappropriate.  A 
prescription for an antibiotic will be deemed unnecessary if an 
ICD-9 code for an infectious disease is not associated with the 
patient encounter. 
 
For each antibiotic prescription identified, a Prescribed 
Therapeutic Regimen (PTR) is calculated by determining a total 
amount of antibiotic prescribed for each patient episode:  PTR 
= Antibiotic Dose (mg or units) x Frequency (times a day) x 
Duration (days).  For the indications of interest, a 
Recommended Therapeutic Regimen (RTR) is calculated to 
determine the appropriateness of the antimicrobial regimen:  
RTR = Antibiotic Dose (mg or units) x Frequency (times a day) x 
Duration (days).  Data used in RTR calculations were derived 
from published guidelines for the selected indications (Table 
3).18-24  Data regarding the recommended dose adjustment for 
renal function were gathered for each antibiotic (Lexicomp 
version 2.3.2) and RTR ranges calculated for each level of renal 
function as appropriate.  For each antimicrobial recommended 
by a treatment guideline, a maximum (RTRmax) and minimum 
(RTRmin) RTR are calculated for each level of renal function by 
multiplying the upper end of the recommended dose by the 
longest recommended duration and the lower end of the 
dosing recommendation by the shortest recommended 
duration, respectively (Table 3).  Exceptions to this rule are 
made for agents that have specific durations associated with 
explicit doses (e.g., for community-acquired pneumonia, 
levofloxacin can be dosed as either 750 mg once daily for 5 
days or 500 mg once daily for 7-14 days).  RTR data were 
compiled in a Microsoft Excel spreadsheet.   
 
The appropriateness of a given course of antimicrobial therapy 
is gauged according to a two-step process.  First, the 
prescribed agent is compared to the RTR database for the 
given indication to determine if the agent is listed as a 
recommended by published guidelines.  Second, if the use of 
the agent prescribed is recommended for an indication within 
the guidelines, the appropriateness of the prescribed dosing 
regimen is assessed by determining if the PTR falls within the 
age and renal function adjusted RTRmin-RTRmax range. 
 
Summary reports for antibiotic prescription rates and 
appropriateness are generated for the entire clinic, individual 
clinics, individual prescribers, and by indication.  These reports 
are used to identify opportunities for education/intervention 
and to assess the impact of these actions. 
 
Significance 
It has been documented that antibiotics are frequently 
prescribed for non-bacterial infections, in suboptimal regimens 
and without regard to spectrum of activity.3-12  These patterns 
of excessive or inappropriate use of antibiotics have been 
linked to the emergence of resistance.1-3  To help preserve the 
utility of the antibiotics currently available, strategies for 
tracking antimicrobial use with subsequent application of 
antimicrobial stewardship principles have advocated.25  For 
almost 20 years now, antimicrobial stewardship programs 
have been used within institutions to successfully improve 
antibiotic usage patterns.  Although analogous programs in the 
outpatient setting have been lacking, publication of Executive 
Order 13676 has stimulated interest in this area.  Before 
programs can be developed to improve antibiotic usage 
patterns, there is a need to develop a standardized and 
accepted way to quantify and assess the appropriateness of 
antibiotic use in the outpatient setting. 
 
Use of prescription records to track outpatient use appears to 
be a good strategy for studying antibiotic usage patterns in the 
outpatient setting.  This approach allows us to assess 
prescriber behavior and based on their intent.  The WHO has 
previously explored the use of prescription data for this 
purpose; however, the methods proposed for assessment of 
the appropriateness utilized comparisons to DDDs.  As 
mentioned, the use of DDD has considerable limitations and 
does not account for disease or patient specific dose 
adjustments.  The method we have developed had the 
advantage in that appropriateness of use and dosing takes 
published treatment guidelines and patient factors such as 
age, weight, and renal/hepatic function into consideration.  
For example if a patient is allergic to a preferred regimen and 
the provider prescribes an alternate agent, the choice of agent 
may be justified.  For age and weight these parameters can be 
important when assessing regimens for pediatric or morbidly 
obese patients. This approach provides much more useful 
information to the clinician as it provides feedback based upon 
evidence-based recommendations. We believe that the 
method we propose not only overcomes some of the 
limitations of DDD, but also combines quality indicators of 
both antibiotic utilization and a process measure (e.g. 
appropriate therapy). 
 
Since most of the prescriptions are transmitted electronically 
to pharmacies, a variety of options were available to us to 
gather prescription data.  Requesting transaction requests 
from an e-prescription network such as Surescripts may have 
allowed us to gather the antibiotic usage data we desired; 
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however, timeliness, cost, and adequacy of the data were 
concerns.  Additionally, upon discussing our plan with our 
information technology department, it was believed that use 
of data contained with our EMR would provide us the most 
efficient means by which to collect prescription data and link it 
to patient specific information.   
 
This approach has not been without limitations and potential 
drawbacks.  For example, it was noted that depending on the 
EMR used, doses may not be entered as a numeric field rather 
a product strength was entered.  This translates into data 
being captured as a text field as opposed to a numeric field 
and thus requires conversion.  Also, if an antibiotic dose or 
duration were to be changed following consultation with the 
dispensing pharmacy and not recorded in the EMR the actual 
PTR would not be reflected.  Lastly, it may be somewhat time 
consuming for IT to determine how data can be extracted for 
specific systems.  However, once appropriate data fields have 
been identified, it will likely become much easier to generate 
results.  
 
The approach we have described is an efficient means to track 
and assess antimicrobial use by outpatient providers.  We 
believe that this strategy could become a standardized model 
for tracking and assessing outpatient antibiotic use.    
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Table 1:  Examples of data fields extracted from the EMR 
Data Field Purpose of Evaluation 
Allergies Determine if use of a recommended agent was contraindicated based on history 
of allergic reaction. 
Allergy Reaction Determine if use of a recommended agent was contraindicated based on history 
of allergic reaction. 
Appointment Provider Determine which clinician prescribed the antimicrobial. 
Demographic data (i.e, age and 
weight) 
Determine appropriateness of the agent and dose selected. 
Encounter Date Identify when the antimicrobial use episode occurred in order to link laboratory 
data and additional encounters. 
ICD-9/Assessment Code Identify infectious condition for which the antimicrobial was prescribed. 
Medical Record Number Group data for an individual patient together. 
Medication Name Identify antimicrobial use episode. 
Medication Signetur Allow for calculation of PTR. 
Medication Status Identify active and discontinued medications. 
Next Patient Appointment Identify follow-up visits for the same condition. 
Provider Role Identify primary physician, resident, or physician’s assistant. 
Serum creatinine and 
glomerular filtration rate 
Determine if the agent was dose appropriately for renal function. 
 
 
 
 
 
 
Table 2: Diagnosis codes for selected infections:18 
Diagnosis ICD-9 Code 
Urinary Tract infection 599.0, 595.0, 595.9 
Unspecified local infection of skin and subcutaneous tissue 680.x-682.x 
Pneumonia, organism not specified 486 
Acute bronchitis 466.x 
Streptococcal sore throat 034.0 
Pneumococcal pneumonia 481 
Acute sinusitis 461.x 
Chronic sinusitis 473.9 
Otitis  381.x - 382.9 
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Table 3:  Calculated antimicrobial RTRmin-RTRmax ranges for adults treated as outpatients with selected indications.
19-24 
Indication Antimicrobial CrCl 
(mL/min) 
Recommended Daily Dose Range Duration 
Range 
(days) 
RTRmin RTRmax 
Rhinosinusitis Amoxicillin/ 
Clavulanate  
>30  
10-29  
<10  
1,500 mg-4,000 mg* 
500 mg-1,000  mg* 
250 mg-500 mg* 
5-7 
5-7 
5-7 
7,500 mg* 
2,500 mg* 
1,250 mg* 
28,000 mg* 
7,000 mg* 
3,500 mg* 
 Doxycycline No 
Adjustment 
200 mg 5-7 1,000 mg 1,400 mg 
 Levofloxacin >50 
>20-49  
10-19  
500 mg 
250 mg 
125 mg 
5-7 
5-7 
5-7 
2,500 mg 
1,250 mg 
625 mg 
3,500 mg 
1,750 mg 
875 mg 
 Moxifloxacin No 
Adjustment 
400 mg 5-7 2,000 mg 2,800 mg 
Streptococcal 
Pharyngitis 
Amoxicillin >30 
>10-29 
<10  
1,000 mg 
500 mg-1,000 mg  
250 mg-500 mg 
10 
10 
10 
10,000 mg 
5,000 mg 
2,500 mg 
10,000 mg 
10,000 mg 
5,000 mg 
 Penicillin VK No 
Adjustment 
1,000 mg 10 10,000 mg 10,000 mg 
 Benzathine 
Penicillin 
No 
Adjustment 
1.2 MU 1 1.2 MU 1.2 MU 
 Cephalexin >10 
<10 
1,000 mg 
250 mg-1,000 mg 
10 
10 
10,000 mg 
2,500 mg 
10,000 mg 
10,000 mg 
 Cefadroxil >10 
<10 
1,000 mg 
667 mg 
10 
10 
10,000 mg 
6,670 mg 
10,000 mg 
6,670 mg 
 Clindamycin No 
Adjustment 
900 mg 10 9,000 mg 9,000 mg 
 Azithromycin No 
Adjustment 
500 mg on day 1 
250 mg on days 2-5 
5 1,500 mg 1,500 mg 
 Clarithromycin >30 
<30 
500 mg 
250 mg 
10 
10 
5,000 mg 
2,500 mg 
5,000 mg 
2,500 mg 
Community-
Acquired 
Pneumonia 
Azithromycin No 
Adjustment 
500 mg on day 1 
250 mg on days 2-5 
5 1,500 mg 1,500 mg 
 Clarithromycin >30 
<30 
500 mg-1,000 mg 
250 mg-500 mg 
7-14 
7-14 
3,500 mg 
1,750 mg 
7,000 mg 
3,500 mg 
 Doxycycline No 
Adjustment 
200 mg 5-10 1,000 mg 2,000 mg 
 Levofloxacin >50 
20-49 
>10-19 
500 mg-750 mg 
250 mg-375 mg 
125 mg-250 mg 
5-14 
5-14 
5-14 
3, 500 mg 
1,750 mg 
875 mg 
7,000 mg 
3,500 mg 
1,750 mg 
 Gemifloxacin >40 
<40 
320 mg 
160 mg 
5-7 
5-7 
1,600 mg 
800 mg 
2,240 mg 
1,120 mg 
 Moxifloxacin No 
Adjustment 
400 mg 5-14 2,000 mg 5,600 mg 
Uncomplicated 
Cystitis 
TMP/SMX*** >30 
15-29 
320 mg** 
160 mg** 
3 
3 
960 mg** 
480 mg** 
960 mg** 
480 mg** 
 Nitrofurantoin >60 200 mg 5 1,000 mg 1,000 mg 
 Fosfomycin No 
Adjustment 
3,000 mg 1 3,000 mg 3,000 mg 
 Ciprofloxacin >5 500 mg 3 1,500 mg 1,500 mg 
 Levofloxacin >10 250 mg 3 750 mg 750 mg 
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Pyleonephritis Ciprofloxacin >5 1,000 mg 7 7,000 mg 7,000 mg 
 Levofloxacin >50 
20-49 
10-19 
750 mg 
375 mg 
125 mg 
5 
5 
5 
3,750 mg 
1,875 mg 
625 mg 
3,750 mg 
1,875 mg 
625 mg 
 TMP/SMX >30 
15-29 
320 mg** 
160 mg** 
14 
14 
4,480 mg** 
2,240 mg** 
4,480 mg** 
2,240 mg** 
Cellulitis Clindamycin No 
Adjustment 
1,200 mg-1,800 mg 5 6,000 mg 9,000 mg 
 Dicloxacillin No 
Adjustment 
2,000 mg 5 10,000 mg 10,000 mg 
 Cephalexin >50 
>10-49 
<10 
2,000 mg 
1,000mg-1,500 mg 
250 mg-1,000 mg 
5 
5 
5 
10,000 mg 
5,000 mg 
1,250 mg 
10,000 mg 
7,500 mg 
5,000 mg 
 Doxycycline No 
Adjustment 
200 mg 5 1,000 mg 1,000 mg 
 Minocycline No 
Adjustment 
200 mg 5 1,000 mg 1,000 mg 
 TMP/SMX >30 
15-29 
320 mg-640 mg** 
160 mg-320 mg** 
5 
5 
1,600 mg** 
800 mg** 
3,200 mg** 
1,600 mg** 
 Penicillin VK No 
Adjustment 
1,000 mg-2,000 mg 5 5,000 mg 10,000 mg 
 Linezolid No 
Adjustment 
1,200 mg 5 6,000 mg 9,000 mg 
Impetigo Dicloxacillin No 
Adjustment 
1,000 mg 7 7,000 mg 7,000 mg 
 Cephalexin >10 
<10 
1,000 mg 
250 mg-1,000 mg 
7 
7 
7,000 mg 
1,750 mg 
7,000 mg 
7,000 mg 
 Erythromycin No 
Adjustment 
1,000 mg 7 7,000 mg 7,000 mg 
 Clindamycin No 
Adjustment 
1,200 mg-1,600 mg 7 8,400 mg 11,200 mg 
 Amoxicillin/ 
Clavulanate 
>30 
10-29 
<10 
1,750 mg* 
500 mg-1,000 mg* 
250 mg-500 mg 
7 
7 
7 
12,250 
mg* 
3,500 mg* 
1,750 mg* 
12,250 mg* 
7,000 mg* 
3,500 mg* 
 
*Dose based on amoxicillin component 
**Dose based on TMP component 
***TMP/SMX = Trimethoprim/sulfamethoxazole 
 
  
 
 
 
 
 
 
 
